In the present study, human U2OS osteosarcoma cells, expressing wild-type p53, were used to investigate the effect of treatment with Nutlin-3 (a non-genotoxic activator of p53) on p53 binding genes. This evidence concerns the gene TP53 and osteosarcoma.